Open Access Green as soon as Postprint is submitted to ZB.
Tocilizumab in COVID-19 therapy: Who benefits, and how?
Lancet 398, 299-300 (2021)
Publication type
Article: Journal article
Document type
Letter to the Editor
ISSN (print) / ISBN
0140-6736
e-ISSN
0099-5355
Journal
Lancet, The
Quellenangaben
Volume: 398,
Issue: 10297,
Pages: 299-300
Publisher
Elsevier
Publishing Place
Ste 800, 230 Park Ave, New York, Ny 10169 Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Environmental Medicine (IEM)